$24.01−0.32 (−1.32%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Veracyte (VCYT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~23.9%/yr (FY21→FY25), net margin 12.8%, and free cash flow (~$126.6M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+18.7%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲16.0%
517.1
FY21→FY25CAGR +23.9%/yr
Net income ($M)▲174.9%
66.4
FY21→FY25CAGR —
Free cash flow ($M)▲98.5%
126.6
FY21→FY25CAGR —
Diluted EPS▲164.5%
0.82
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+18.7%
67.9mn → 80.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$9.7M
steady at 1.9% of revenue (−14.3% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
13¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 66.1% → 70.1%. Net margin 12.8% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 581,782.0 | 517,145.0 | 445,764.0 | 361,051.0 | 296,536.0 | 219,514.0 | ▲16.0% | +23.9% |
Cost of revenue | 162,439.0 | 154,613.0 | 147,619.0 | 131,367.0 | 120,855.0 | 74,400.0 | ▲4.7% | +20.1% |
Gross profit | 418,785.0 | 362,532.0 | 298,145.0 | 229,684.0 | 175,681.0 | 145,114.0 | ▲21.6% | +25.7% |
Research & development | 109,548.0 | 70,814.0 | 69,294.0 | 57,305.0 | 40,603.0 | 29,843.0 | ▲2.2% | +24.1% |
Selling, general & admin | 97,792.0 | 110,784.0 | 110,610.0 | 86,229.0 | 73,200.0 | 101,353.0 | ▲0.2% | +2.2% |
Total operating expenses | 330,815.0 | 315,421.0 | 293,555.0 | 333,943.0 | 236,035.0 | 227,017.0 | ▲7.4% | +8.6% |
Operating incomefeeds ROC rank | 99,390.0 | 57,777.0 | 16,142.0 | −85,795.0 | −41,081.0 | −81,903.0 | ▲257.9% | — |
Other income, net | 18,863.0 | 10,424.0 | 9,602.0 | 9,183.0 | 4,654.0 | 254.0 | — | — |
Pretax income | 118,253.0 | 68,201.0 | 25,744.0 | −76,612.0 | −36,427.0 | −81,649.0 | ▲164.9% | — |
Income tax | −8,596.0 | 1,848.0 | 1,606.0 | −2,208.0 | 133.0 | −6,086.0 | ▲15.1% | +140.4% (22→25) |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 126,849.0 | 66,353.0 | 24,138.0 | −74,404.0 | −36,560.0 | −75,563.0 | ▲174.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 1.54 | 0.82 | 0.31 | −1.02 | −0.51 | −1.11 | ▲164.5% | — |
Diluted shares (mn) | 82.78 | 80.57 | 78.16 | 72.64 | 71.55 | 67.89 | ▲3.1% | +4.4% |
| Margins | ||||||||
Gross margin61st pct in Healthcare | 72.0% | 70.1% | 66.9% | 63.6% | 59.2% | 66.1% | ▲3.2pp | +4.0pp |
Operating margin | 17.1% | 11.2% | 3.6% | −23.8% | −13.9% | −37.3% | ▲7.6pp | +48.5pp |
Net margin88th pct in Healthcare | 21.8% | 12.8% | 5.4% | −20.6% | −12.3% | −34.4% | ▲7.4pp | +47.3pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Veracyte's revenue last fiscal year?
Veracyte reported revenue of $517.1M in fiscal 2025, up 16.0% from fiscal 2024.
What was Veracyte's net income?
Veracyte reported net income of $66.4M in fiscal 2025, a net margin of 12.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

